Estadísticas

 array:23 [
  "pii" => "S0025775315300075"
  "issn" => "00257753"
  "doi" => "10.1016/S0025-7753(15)30007-5"
  "estado" => "S300"
  "fechaPublicacion" => "2014-12-01"
  "aid" => "70115"
  "copyright" => "Elsevier España, S.L.U.. Todos los derechos reservados"
  "copyrightAnyo" => "2014"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "cita" => "Med Clin. 2014;143 Supl 3:30-4"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 355
    "formatos" => array:2 [
      "HTML" => 241
      "PDF" => 114
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0025775315300087"
    "issn" => "00257753"
    "doi" => "10.1016/S0025-7753(15)30008-7"
    "estado" => "S300"
    "fechaPublicacion" => "2014-12-01"
    "aid" => "70116"
    "copyright" => "Elsevier España, S.L.U."
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Med Clin. 2014;143 Supl 3:35-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 450
      "formatos" => array:2 [
        "HTML" => 240
        "PDF" => 210
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Situaciones especiales en la esclerosis múltiple"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "35"
          "paginaFinal" => "38"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Special cases of multiple sclerosis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Mar Mendibe Bilbao"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Mar"
              "apellidos" => "Mendibe Bilbao"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315300087?idApp=UINPBA00004N"
    "url" => "/00257753/00000143000000S3/v2_201502280340/S0025775315300087/v2_201502280340/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0025775315300063"
    "issn" => "00257753"
    "doi" => "10.1016/S0025-7753(15)30006-3"
    "estado" => "S300"
    "fechaPublicacion" => "2014-12-01"
    "aid" => "70114"
    "copyright" => "Elsevier España, S.L.U."
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Med Clin. 2014;143 Supl 3:23-9"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 386
      "formatos" => array:2 [
        "HTML" => 264
        "PDF" => 122
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Tratamientos orales en esclerosis múltiple"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "23"
          "paginaFinal" => "29"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Oral treatments in multiple sclerosis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "José Eustasio Meca-Lallana, Rocío Hernández-Clares, Ester Carreón-Guarnizo"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "José Eustasio"
              "apellidos" => "Meca-Lallana"
            ]
            1 => array:2 [
              "nombre" => "Rocío"
              "apellidos" => "Hernández-Clares"
            ]
            2 => array:2 [
              "nombre" => "Ester"
              "apellidos" => "Carreón-Guarnizo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315300063?idApp=UINPBA00004N"
    "url" => "/00257753/00000143000000S3/v2_201502280340/S0025775315300063/v2_201502280340/es/main.assets"
  ]
  "es" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Anticuerpos monoclonales para el tratamiento de la esclerosis múltiple"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "30"
        "paginaFinal" => "34"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Victoria Galán Sánchez-Seco, Ignacio Casanova Peño, Rafael Arroyo González"
        "autores" => array:3 [
          0 => array:2 [
            "nombre" => "Victoria Galán"
            "apellidos" => "Sánchez-Seco"
          ]
          1 => array:2 [
            "nombre" => "Ignacio"
            "apellidos" => "Casanova Peño"
          ]
          2 => array:4 [
            "nombre" => "Rafael"
            "apellidos" => "Arroyo González"
            "email" => array:1 [
              0 => "rafaelarroyo09@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Unidad de Enfermedades Desmielinizantes&#44; Hospital Cl&#237;nico San Carlos&#44; Madrid&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#42;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Monoclonal antibodies for the treatment of multiple sclerosis"
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec464975"
          "palabras" => array:8 [
            0 => "Esclerosis m&#250;ltiple"
            1 => "Natalizumab"
            2 => "Alemtuzumab"
            3 => "Daclizumab"
            4 => "Rituximab"
            5 => "Ocrelizumab"
            6 => "Ofatumumab"
            7 => "BIIB033"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec464974"
          "palabras" => array:8 [
            0 => "Multiple sclerosis"
            1 => "Natalizumab"
            2 => "Alemtuzumab"
            3 => "Daclizumab"
            4 => "Rituximab"
            5 => "Ocrelizumab"
            6 => "Ofatumumab"
            7 => "BIIB033"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hasta mediados de los a&#241;os noventa&#44; con la aparici&#243;n del interfer&#243;n beta y el acetato de glatir&#225;mero&#44; no exist&#237;a tratamiento para la esclerosis m&#250;ltiple &#40;EM&#41;&#46; Sin embargo&#44; debido a su moderado potencial terap&#233;utico en algunos pacientes&#44; se continu&#243; con una amplia b&#250;squeda encaminada a encontrar nuevas y m&#225;s efectivas estrategias de tratamiento&#44; centrando buena parte de los esfuerzos en los anticuerpos monoclonales &#40;AcMo&#41;&#46; A finales de 2004 fue aprobado natalizumab&#44; el primer AcMo para el tratamiento de la EM&#44; que represent&#243; un important&#237;simo avance en el campo de la neuroinmunolog&#237;a&#46; Hoy en d&#237;a&#44; la experiencia con natalizumab es amplia y existen otros AcMo &#40;alemtuzumab&#44; daclizumab&#44; rituximab&#44; ocrelizumab&#44; ofatumumab y anti-lingo-1&#41; pendientes de comercializar&#44; o en fases II y II de estudio con resultados prometedores&#46; En esta revisi&#243;n se analizan los resultados de eficacia y seguridad de todos ellos&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Until the mid 1990s&#44; with the appearance of interferon beta and glatiramer acetate&#44; there was no treatment for multiple sclerosis &#40;MS&#41;&#46; However&#44; due to their moderate therapeutic potential in some patients&#44; a broad search was continued to find new and more effective treatment strategies&#44; largely concentrated on monoclonal antibodies &#40;MOAB&#41;&#46; Natalizumab&#44; the first MOAB for the treatment of MS&#44; was approved at the end of 2004&#44; representing a major advance in the field of neuroimmunology&#46; Today&#44; there is broad experience with natalizumab and other MOAB &#40;alemtuzumab&#44; daclizumab&#44; rituximab&#44; ocrelizumab&#44; ofatumumab and anti-lingo-1&#41; that are pending commercialization or are under phase II or III of development with promising results&#46; The present review analyzes the efficacy and safety results of all these drugs&#46;</p></span>"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00257753/00000143000000S3/v2_201502280340/S0025775315300075/v2_201502280340/es/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/00257753/00000143000000S3/v2_201502280340/S0025775315300075/v2_201502280340/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315300075?idApp=UINPBA00004N"
]